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Abstract
A cocoon vaccination strategy refers to vaccinations in persons from the immediate envi-
ronment of those patients who might develop an illness (they are susceptible to illnesses) 
but cannot be vaccinated due to permanent or temporary medical contraindications to 
a vaccination (e.g. immunosuppressed patients) or are too young to have a vaccination. 
Most frequently, a cocoon vaccination strategy is associated with vaccinations in adults 
aimed at preventing the spread of an illness in children (e.g. pertussis vaccination or 
influenza vaccination), but it is worth considering whether this strategy should not be 
understood also as vaccinations in children with the view of protecting adults and the 
elderly against illnesses (e.g. influenza or pneumococcal diseases). The aim of the cocoon 
strategy is to minimize the risk of the transmission of pathogens in the environment of a 
patient who is susceptible to an infection. A vaccinated patient is not a source of infection 
any more for a non-vaccinated patient. The chapter presents a history, current implemen-
tation of the strategy in different countries, its benefits and limitations.
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1. Introduction
Immunization methods cover [1]:
1. routine vaccinations in children and adolescents under national immunization programs,
2. vaccinations in adults from risk groups (due to clinical recommendations, e.g. chronic dis-
eases, and epidemiological recommendations, e.g. occupation, scheduled travels),
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
3. ring vaccination strategy (vaccination of a ring of close contacts of an ill person; it is a strat-
egy used to stop an epidemic, as in the case of smallpox eradication in India) and
4. cocoon vaccination strategy.
A cocoon vaccination strategy refers to vaccinations in persons from the immediate 
 environment of those patients who might develop an illness (they are susceptible to illnesses) 
but cannot be vaccinated due to permanent or temporary medical contraindications to a 
 vaccination (e.g. patients in immunosuppression) or are too young to have a vaccination [1].
Most frequently, a cocoon vaccination strategy is associated with vaccinations in adults aimed 
at preventing the spread of an illness in children (e.g. pertussis vaccination or influenza vac-
cination), but it is worth considering whether this strategy should not be understood also as 
vaccinations in children with the view of protecting adults and the elderly against illnesses 
(e.g. influenza or pneumococcal diseases) [1].
The aim of the cocoon strategy is to minimize the risk of the transmission of pathogens in 
the environment of a patient who is susceptible to an infection. A vaccinated patient is not a 
source of infection any more for a non-vaccinated patient [1, 2].
2. Cocoon strategy and environmental immunity
The concept of a cocoon vaccination strategy is connected with herd immunity and herd 
immunity threshold [3].
Herd immunity is a term that was coined as a result of observations which showed that 
the presence of persons immune to a particular infectious disease in a certain population 
decreases the probability of developing this disease by other persons in this population who 
are not immune to this disease. The earliest observation of this phenomenon was made in 
1840 by an outstanding British hygienist, William Farr, who wrote in his report on births, 
deaths and marriages in England and in Wales that “smallpox transmission might be inter-
rupted or sometimes stopped thanks to vaccinations which protect a part of the population” 
[3]. However, the very term “herd immunity” was used by Topley and Wilson for the first 
time. In their studies into epizootic in mice under laboratory conditions, they concluded that 
“immunity understood as a characteristic of a herd should be approached scientifically as 
a separate issue that is closely related to immunity of particular specimens, but at the same 
time constitutes a different issue in many aspects” [3]. The essence of herd immunity is that 
the higher the proportion of specimens immune to a disease in a population, the lower the 
probability of developing the illness by a specimen with no immunity to the disease. Thus, 
the term can be used with reference to infectious diseases in which some specimens infect the 
others [3].
Herd immunity threshold is the proportion of persons who need to be immune in order to 
stop an infectious disease from spreading in a population. For most diseases, it is over 80% 
[3]. Herd immunity threshold is influenced by the following factors: transplacental immunity, 
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patient’s age at the time of vaccination, age-related differences in the frequency of contacts 
or in infection risks (as the result of the decrease in the frequency of contacts, the real herd 
immunity threshold is lower than the estimated one), seasonal changes in the frequency of 
contacts (the period of decreased seasonal infectivity decreases the real herd immunity thresh-
old as compared to the estimated threshold), geographical heterogeneity and social structure 
(irregularities of risk distribution in various social groups) [3]. Herd immunity threshold for 
pertussis is high, and it amounts to 92–94%. However, considering the decrease in infectivity 
with age and the seasonality of the disease the estimates indicate 88% [3].
Population-based vaccine efficacy depends on a high proportion of the vaccinated individu-
als in a population. A good example may be measles, a highly contagious disease, which 
has become a re-emerging disease in countries where the proportion of those vaccinated has 
diminished (e.g. Germany, Great Britain) [4]. Population protection (herd immunity) result-
ing from breaking the infection transmission with the use of vaccinations has been observed 
in Australia for vaccinations against rotaviruses (e.g. after the introduction of common vacci-
nations against rotaviruses, the frequency of hospitalizations due to acute diarrhea decreased) 
and vaccinations against human papillomavirus (HPV), as well as in Great Britain for vaccina-
tions against Haemophilus influenzae type b and the meningococcal group C [5].
3. Cocoon strategy against pertussis
Pertussis is a contagious bacterial disease of the respiratory system caused by gram-neg-
ative rod Bordetella pertussis. Infection is transmitted through droplets or contact, and the 
source of infection is an ill person (there are no carriers) [6]. The disease can be developed 
in people who have not been vaccinated, fully vaccinated, properly vaccinated or who were 
vaccinated against pertussis a long time ago, as well as those who have already suffered 
from it because infection-acquired immunity to pertussis lasts only up to 20 years. The incu-
bation period of the disease ranges from 7–14 to 22 days [6]. In total, the illness lasts up 
to 3 months, which is why it was called a 100-day cough in the Chinese medicine. The 
most serious pertussis complications occur most frequently in newborns and infants, and 
they include pneumonia, other bacterial or viral superinfections, segmental atelectasis and 
replacement emphysema, pertussis encephalopathy, seizures and encephalitis [6]. Mortality 
rate amounts to 0.1–4% [7–9].
Since mid-1980s, it has been observed that the epidemiological situation of pertussis in devel-
oped European countries, North America, Australia and Japan has been deteriorating. This 
results from the decrease in post-vaccinal immunity, which is not lifelong, but it lasts for 
5–10 years. Currently, the highest incidence of pertussis is reported in adolescents and adults, 
and the representatives of these age groups are the main known source of infection for new-
borns and young infants who were not vaccinated against pertussis (in most countries, the first 
vaccination is given in the 6th week of life), were vaccinated with a delay or did not receive the 
required number of vaccination doses [7, 8]. It was found that the source of Bordetella pertussis 
infection in 30–75% of disease cases in newborns hospitalized for pertussis was persons from 
newborns’ immediate environment (mothers, fathers or older siblings) (Table 1) [9–12].
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Currently used strategies for pertussis prevention include [13–15] are listed below:
1. vaccinations in infants and small children, TDPw or TDPa vaccines,
2. booster vaccinations in children of pre-school age, TDPa or Tdpa vaccines, and in children 
of the school age (adolescents), Tdpa vaccine,
3. booster vaccinations in adults (recommended every 10 years), Tdpa vaccine,
4. vaccinations in pregnant women, Tdpa vaccine and
5. cocoon strategy for protective vaccination, Tdpa vaccine.
TDPw vaccines contain a whole cell pertussis component and may be used in infants older 
than 6 weeks till 36 months of age. However, due to a higher reactogenicity related to TDPw 
compared to TDPa vaccines [16, 17], the majority of high-income countries implemented 
TDPa vaccines into the national immunization schedules. On the other hand, it was reported 
that the duration of the immunity after TDPa vaccines may be shorter than TDPw vaccines 
[18]. Table 2 illustrates differences between TDPa and Tdpa vaccines. Tdpa vaccines contain a 
reduced antigen content, and they are recommended for individuals older than 4 years of age.
In response to the alarming increase in pertussis morbidity in 2001, Global Pertussis Initiative 
(GPI) consisting of experts from 17 countries was established. In 2005, the  organization 
Author Results (source of pertussis)
Bonmarin et al. [9] Parents 55%
Siblings 25%
Others 17%
Bisgard et al. [10] Mother 32%
Father 15%
Siblings 20%
Grandparents 8%
Others 25%
Wendelboe et al. [11] Adults 48–55%
Siblings 16–21%
Others 18–29%
Kowalzik et al. [12] Mother 63%
Father 13%
Siblings 21%
Others 30%
Table 1. Adults and adolescents as the main source of Bordetella pertussis infection in newborns [9–12].
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 recommended the increase and extension of the scope of vaccination strategies and the 
 implementation of booster vaccinations against pertussis in adolescents in developed  countries. 
Special attention was drawn to pertussis prevention in newborns and infants who belong to 
the group, which is subject to the highest risk of severe pertussis. Three vaccination strategies 
were considered: vaccinations in mothers, vaccinations in newborns and cocoon strategy. On 
the basis of mathematical modeling, GPI estimated that routine vaccinations in adolescents 
connected with the cocoon strategy might diminish pertussis morbidity by 50%. These esti-
mates resulted in national and international expert groups’ recommendations in 2006 to intro-
duce cocoon strategy in all countries, which have appropriate measures to do this [19].
Cocoon strategy involves administration of Tdpa to persons who have a close contact with 
newborns and infants (of up to 12 months of age), parents, grandparents, caregivers and 
older siblings. Optimal time of vaccination is at least 2 weeks before an expected contact with 
a child [14]. Strategies of vaccinations against pertussis in selected European countries are 
 presented in Table 3.
In 2006, the Advisory Committee on Immunization Practices (ACIP) recommended routine 
Tdpa vaccination in adults who have or are likely to have a close contact with children of up 
to 12 months of age. In 2011, ACIP decided that this recommendation should be extended and 
include vaccinations in adults above the age of 65 years, for example, grandparents, nursery 
and kindergarten employees as well as healthcare facility staff [14]. Currently, cocooning is 
recommended not only by ACIP but also by American Academy of Pediatrics (AAP) and 
American Academy of Family Physicians (AAFP) [21].
It is estimated that 605 persons from immediate and distant environments of an infant have 
to be vaccinated in pertussis epidemiological situation in the USA in order to prevent one 
disease case, whereas in the case of vaccinations in adolescents, in order to observe the same 
effect, a four-times bigger group needs to be vaccinated, that is, 2325 persons [14]. This can be 
explained by the fact that although small children are the source of infection for other popu-
lation groups in most infection cases (e.g. influenza, pneumococcal infections), in the case of 
pertussis, an opposite situation can be observed. Common vaccinations in infants and small 
children have resulted in the transmission of the disease to older age groups and thus house-
hold members, parents and adolescents have become the source of infection [6, 14].
Contents of 0.5 ml of vaccine TDPa Tdpa
Diphtheria toxoid >30 IU >2 IU
Tetanus toxoid >40 IU >20 IU
Pertussis antigens: 8.0 μg 2.5 μg
Pertactin 25.0 μg 8.0 μg
Pertussis toxoid 25.0 μg 8.0 μg
Filamentous hemagglutinin
Table 2. Differences between TDPa and Tdpa vaccines [6].
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Although cocoon strategy against pertussis is accepted by caregivers of young children, its 
implementation is at a low level. According to the data of 2008, only 5% of adults who had 
a close contact with infants were given Tdpa vaccinations [14]. Leboucher et al. [22] showed 
that the idea of cocooning was accepted by 97% of parents of newborns, which resulted in 
vaccinations in 69% of mothers and 63% of fathers. In 96% of cases, vaccinations were done 
under the conditions of ambulatory healthcare (at a family doctor) [22]. Decréquy et al. [23] 
observed that before the cocooning program was implemented on a chosen maternity ward, 
only 20% of mothers and 13% of fathers had been vaccinated against pertussis, whereas after 
Country Basic vaccination Booster vaccinations in 
children and adolescents
Booster vaccinations in 
adults
Austria 2–4–6 months 12–24 months, Every 10 years
13–16 years
Belgium 2–3–4 months 15 months Cocoon strategy
5–7 years, 14–16 years
Finland 3–5–12 months 4 years, –
14–15 years
France 2–3–4 months 16–18 months, 11–13 years 27–28 years, all healthcare 
employees (2008)
Cocoon strategy
Germany 2–3–4 months 5–6 years, 11–15 years Cocoon strategy
Healthcare employees 
(2003)
Italy 3–5–11 months 5–6 years, –
11–15 years
Netherlands 2–3–4 months 11 months –
14 years
Poland 2–4–6 months 18–18 months, Healthcare employees who 
have contact with infants 
(2015);
6 years, 14 years Adults > 19 years—every 
10 years
Cocoon strategy (2015)
Switzerland 2–4–6 months 15–24 months –
4–7 years (11–15 years, 
catch up)
Luxembourg 12 months 5–6 years, Every 10 years
15–16 years
Table 3. Strategies of vaccinations against pertussis in particular European countries [20].
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the  introduction of educational activities, the level of vaccinations increased to 77% in  mothers 
and 57% in fathers. It was indicated that the continuation of vaccinations is necessary, not 
only at a local but also at a national level [23].
A few reasons that prevent cocoon strategy against pertussis from being commonly imple-
mented and accepted were identified. It was indicated that to improve the cocooning strategy, 
it is required to combine parental education with free vaccinations in pediatric or maternal 
settings [14, 22]. However, implementation of the cocoon strategy on maternity and neonatal 
wards as well as in pediatric centers requires resources from a doctor to undertaking activi-
ties, which go beyond their scope of standard duties, not to mention financial issues related to 
costs and refunds. Furthermore, implementation of this strategy requires substantial financial 
resources and the increase in the number of healthcare personnel [6].
Currently, data evaluating the effectiveness of a cocoon strategy are limited. Skowronski et al. 
[24] suggested that cocooning may not be cost-effective in areas where a disease incidence is 
low. The authors concluded that it would take 1 million parental immunizations to save one 
infant death, 100,000 parental immunizations to save one infant’s intensive care unit admis-
sion and 10,000 parental immunizations to prevent one infant’s hospitalization [24]. However, 
Westra et al. from the Netherlands found that maternal immunization or a cocooning pro-
gram for both parents was cost-effective and even cost-saving [25] as compared to just an 
infant immunization program. Healy and Baker [26] found that up to 75% of infant pertussis 
cases are acquired from a household contact, and cocooning could lead to a 70% reduction in 
pertussis cases in infants of less than 3 months of age.
The concept of “number needed to treat” to estimate the number of adults that would need 
to be vaccinated (NNV) to prevent one case of disease, hospitalization and death due to per-
tussis was used and described by researchers from Ontario (Canada) [2]. After implementa-
tion of the cocoon strategy against pertussis, the NNV to prevent one case, hospitalization or 
death from pertussis was between 500–6400, 12,000–63,000 and 1.1–12.8 million, respectively 
(after adjusting for under-reporting). Rarer outcomes were associated with higher NNV [2]. 
The authors also demonstrated that NNV estimates for pertussis vary greatly depending on 
the frequency of the outcome, including the target age group, the degree of under-reporting 
believed to be in existence, the assumed vaccine effectiveness (VE) and the estimated propor-
tion of infants infected by the mother and the father. It was concluded that the objectives of 
implementing a cocoon immunization strategy must be carefully considered if the strategy 
should be evaluated properly. If the objective of the program is to prevent pertussis in the 
population in general, a universal strategy should be considered. However, if the objective 
is to prevent deaths due to pertussis, a large number of adults need to be vaccinated [2]. A 
similar conclusion was presented by Italian authors [27].
The cocoon strategy against pertussis was implemented in the USA in 2006. Data from two 
small studies reported conflicting results. One study documented a 50% decline in the inci-
dence of pertussis in hospitals with a post-partum Tdap vaccination policy in 2006 (n = 48), 
while a 20% increase was observed among hospitals that did not have such a policy (n = 145) 
[28]. In contrast, Castagnini et al. [29] found no difference in the rates of illness, length of 
hospitalization or mortality in infants under 6 months of age when post-partum women were 
Cocoon Strategy of Vaccinations: Benefits and Limitations
http://dx.doi.org/10.5772/intechopen.68890
9
vaccinated prior to discharge. The authors recommended that all household members and 
key contacts of newborns should be immunized instead. There is also evidence that immuni-
zation coverage of high-risk groups increases when vaccination programs are universal rather 
than targeted [30, 31].
4. Vaccinations against influenza in cocoon strategy
Influenza is a severe infectious disease caused by Orthomyxoviridae viruses. Influenza in child 
population is an undervalued, not to say underestimated, problem. This might result from 
the fact that disease symptoms are non-specific and the disease diagnostics is quite difficult, 
although accessible and feasible both on an outpatient and on an inpatient basis [32]. It is 
estimated that influenza virus infections cause 10–40% of acute febrile respiratory tract infec-
tions in children annually; however, in closed environments this rate might amount even to 
50% [33].
In the course of establishing worldwide influenza in children at the age of below 5 years in 
2008, Nair et al. [34] estimated, on the basis of an analysis of 43 studies, that in that year there 
were 90-million influenza cases in the mentioned age group globally. A 13% of cases developed 
acute lower respiratory insufficiency (ALRI) and 28,000–111,500 cases resulted in death [34].
Occurrence of severe seasonal influenza cases in children and adolescents is described by the 
number of deaths and the number of hospitalizations in intensive care units. The actual occur-
rence of influenza in children is underestimated due to the fact that children who suffer from 
mild influenza are not even consulted on an outpatient basis [32, 33].
In comparison with adults, children who suffer from influenza, especially infants below the 
age of 1 year, require a higher number of consultations on an outpatient basis [35]. According 
to the study, 24% of all outpatient influenza-related visits concerned children [36]. A big num-
ber of outpatient visits related to influenza and its complications generates not only direct 
costs but also indirect costs that are, for example, connected with the child caregivers’ absence 
from work and the loss of earnings [36]. Furthermore, these visits constitute an organizational 
challenge for medical facilities. The number of hospitalizations related to influenza and its 
complications in children in the USA is estimated to amount to 0.9/1000 children, and most of 
them concern children at the age of below 1 year [37]. The risk of influenza-related hospital-
izations in children of pre-school age is comparable to the risk that is observed in the group 
of the elderly above the age of 65 years [37]. The number of hospitalizations for influenza in 
children at the age of up to 5 years amounts to 5/10,000 children and in adolescents, 1/10,000 
persons [37]. A study by Rhim et al. [38] demonstrated that 7.3% of children who reported 
to admission rooms in pediatric hospitals due to influenza-like symptoms required hospital-
ization, whereas a study by Irving et al. [39] showed that 5% of outpatients diagnosed with 
influenza required hospitalizations.
Influenza mortality in children is estimated at <1/100,000 patient-treatment years and unfor-
tunately most deaths (even up to 50%) occur in children with no additional disease burden 
[40]. Deaths due to influenza in children are rare. In the USA in 2003/2004, mortality in this 
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group of patients amounted to 2.1/1,000,000 [40]. In the twentieth and twenty-first centuries, 
influenza can be effectively prevented with vaccinations. It is worth noticing that influenza 
deaths in children occur also in those children who suffer from no additional burdening dis-
eases that could classify them as patients who are subject to the risk of the severe course of the 
disease. For example, in 2003/2004 in Great Britain, 17 deaths due to influenza in children and 
adolescents aged below 18 years were observed and they all occurred in patients who were 
initially healthy [41]. Furthermore, sudden deaths in children caused by influenza B virus 
infections were reported. The causes of deaths were determined only in an autopsy (concern-
ing intravital diagnosis, there were no symptoms from the respiratory system but from the 
digestive system) [42].
Cocoon strategy in influenza prophylaxis was created on the basis of data concerning cocoon 
strategy in pertussis prevention. Justification of cocoon strategy for influenza is different than 
for pertussis because no influenza vaccination can be used in infants aged below 6 months 
due to low immunogenicity in this age group. As mentioned above, the risk of hospitaliza-
tion in infants due to influenza is particularly high, and the greatest risk concerns children 
aged below 6 months. The frequency of influenza hospitalizations in healthy infants is similar 
to the frequency of hospitalizations in adults who are in a high-risk group. Therefore, effec-
tive solutions are necessary to provide appropriate protection for this particularly susceptible 
population group. Influenza prophylaxis includes hand hygiene, avoiding contact with the ill 
and vaccinations in persons who have a close contact with the ill.
In the first year of their lives, newborns whose mothers were not vaccinated against influenza 
either have no immunity to influenza viruses or they have low adaptive immunity. Therefore, 
it is recommended to vaccinate household members and caregivers of infants at the age below 
6 months. Such vaccinations should result in the increase in children protection through creat-
ing a protective cocoon. Not all adults are aware of the importance of influenza vaccinations 
in adults and in children. In order to increase the number of vaccinated persons, it is necessary 
to provide educational activities and develop initiatives addressed not only at the employees 
of healthcare facilities but also at patients.
Time is another factor that limits the implementation of cocoon strategy in influenza pro-
phylaxis. The strategy can be effective only when all persons from the immediate environ-
ment of a newborn, as well as newborn’s relatives and caregivers, are vaccinated at least 
4 weeks before the child is born because an immunologic response to a vaccination requires 
time. Gynecologists and obstetricians should propose vaccinations to women on their vis-
its to health centers before they become pregnant or during the pregnancy. After persons 
from the immediate environment have been vaccinated, another method of infants’ pro-
tection against influenza is vaccinations in pregnant women. A recent study conducted in 
Bangladesh, which evaluated vaccinations against influenza in pregnant women, showed 
that the number of laboratory-confirmed influenza cases in infants of vaccinated mothers 
decreased by 63% [43].
Cocoon strategy encourages education of patients and employees of healthcare facilities. 
Educational activities might increase the percentage of the vaccinated population. In families, 
the main sources of infections for newborns and infants are parents and siblings.
Cocoon Strategy of Vaccinations: Benefits and Limitations
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Studies show that providing parents of newborns with information on the benefits of influ-
enza vaccinations, as well as providing free-of-charge vaccines, positively influences imple-
mentation of the cocoon strategy. Walter et al. [44] indicated that after such activities had been 
implemented in one maternity hospital, 54.9% of parents underwent vaccinations (vaccina-
tions were given in maternity units and were free of charge for mothers only). Shah et al. [45] 
observed even higher indicators (86.9–95% in two consecutive years in parents of newborns 
in an intensive care unit).
5. Cocoon strategy for vaccinations in contact with immunosuppressed 
patients
Patients in immunosuppression resulting from anticancer or anti-inflammatory treatment 
(inflammatory bowel diseases [IBD], rheumatic diseases) might not achieve appropriate level 
of protection after the vaccination (vaccines that are considered to be safe for this group of 
patients are inactivated vaccines). This is why minimizing the risk of disease transmission 
in those patients’ environment is of significant importance. In particular, influenza, pertus-
sis and chickenpox vaccinations are recommended [46]. Unfortunately, vaccinations in the 
contacts of patients in immunosuppression are at a low level, which proves that education in 
this group is highly necessary. Waszczuk et al. [47] conducted a self-completed survey among 
patients with inflammatory bowel disease (IBD) and reported that the use of recommended 
vaccines in family members of patients was insufficient (22–26%). There was a statistically sig-
nificant association between the non-reimbursed vaccines coverage level and the educational 
status of patients [47].
6. Cocoon strategy for vaccinations in healthcare professionals
Due to frequent contact with the ill, high infectivity of the diseases and lack of life-long immu-
nity to diseases, healthcare personnel belong to a group which is highly at the risk of becom-
ing infected with Bordetella pertussis or influenza virus.
In the case of pertussis, it is estimated that the risk of developing an illness by healthcare pro-
fessionals is almost two times higher as compared with the general population. Serological 
results of one study showed that Bordetella pertussis infection in healthcare professionals 
subject to five-year observations was 2 times higher in 55%, 3 times higher is 17% and 4 times 
higher in 4% of the personnel [48]. Pertussis might become a hospital infection and its source 
might be either a patient or a healthcare personnel. Outbreak of the disease in healthcare pro-
fessionals threatens patients’ health, especially infants’ health. Activities to stop the outbreak 
might be costly and disturb the functioning of a healthcare facility. Ward et al. [49] described 
a pertussis outbreak in a 600-bed general hospital in Paris with 2100 employees. In November 
2000, three pertussis cases in the personnel were observed there. An epidemiological inves-
tigation showed that the first case was a 51-year-old woman who infected three coworkers. 
A local committee for hospital infections decided to conduct screenings in all healthcare 
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employees and patients. Personnel with respiratory symptoms were excluded from work for 
the first 5 days of antibiotic treatment. Eventually, pertussis was diagnosed in 17 persons, 
including 15 members of the personnel and 2 patients. The cost of controlling the outbreak, 
mostly diagnostic tests, treatment and the loss of productivity, amounted to over 46,000 Euro.
Baggett et al. [50] described two pertussis outbreaks in hospitals in King county in the United 
States of Washington which occurred in 2004:
1. In the first hospital, the source of infection was a 38-year-old doctor who worked on an 
emergency ward (at that moment when she developed the illness, she was in the 37th week of 
pregnancy, coughing fits and vomiting after the fits lasted for 37 days, and the doctor associ-
ated them with the exacerbation of concurrent bronchial asthma). Epidemiological investiga-
tion identified five probable cases, which met the pertussis clinic definition of Centers for 
Disease Control and Prevention (CDC) at that time, and two cases were confirmed. Disease 
cases concerned two nurses, a receptionist, a close friend of the infected doctor and the doc-
tor’s husband. The woman put 738 persons at risk of infection, including 388 hospital workers, 
265 patients and 85 visitors. Among them, 600  persons were examined (80%) and 516 persons 
were administered antibiotics. Furthermore, one patient who was admitted to the hospital for 
an emergency appendicitis operation and had contact with the infected doctor in the admis-
sion room had a positive polymerase chain reaction (PCR) result without typical clinical 
symptoms. This resulted in testing 95 persons who had contact with the infected woman (92 
persons were given antibiotics) and 29 PCR tests (all results were negative). Hospital pertus-
sis outbreak had significant economic and organizational consequences. The costs included 
diagnostic tests, antibiotics for all hospital employees with respiratory symptoms who had 
contact with the persons diagnosed with pertussis and excluding them from work for the first 
5 days of treatment and
2. In the other hospital, a 38-year-old physiotherapist working in an intensive care pediat-
ric unit visited a company doctor due to persistent coughing fits which lasted for 22 days. 
Although the cultivation and testing of the PCR material from nasopharynx were negative 
and so was the direct immunofluorescence test, an epidemiological investigation was initi-
ated since clinical criteria were fulfilled by the physiotherapist. Pertussis was diagnosed and 
confirmed in three nurses from the intensive care unit and in one resident doctor who had 
contact with the ill person. It was estimated that 417 hospital workers, 200 hospital visitors 
and 120 patients were potentially exposed to the disease. Bordetella pertussis infection was 
confirmed with the PCR method in four members of the hospital personnel. At the expense 
of the hospital, antibiotics were administered to 343 workers and 70 visitors and patients. 
Employees with respiratory symptoms were expelled from work for 1 day until obtaining the 
negative PCR result. The costs of activities connected with controlling the outbreaks exceeded 
260,00 US dollars in the first hospital and 120,000 US dollars in the other hospital, and they 
were connected mostly with the costs of overtime related to expelling persons at risk of per-
tussis from work and with remuneration for additional work for the hospital infection team.
Calugar et al. [51] focused on cost-effectiveness of pertussis vaccinations in healthcare person-
nel. They analyzed a pertussis outbreak which occurred in 2003 in a specialist clinic in the 
USA after a 1-day exposure of healthcare personnel to an infant with a confirmed pertussis 
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diagnosis [51]. Three hundred and seven members of healthcare personnel were at risk and 
seven of them had symptomatic pertussis. The authors estimated that vaccinations in health-
care professionals would prevent over 46% of pertussis cases, and from the perspective of the 
hospital, they would decrease the costs of controlling the outbreak. The authors concluded 
that pertussis might disturb the functioning of the hospital and that personnel vaccinations 
could decrease the number of infected workers and could enable the hospital to achieve sav-
ings. Members of healthcare personnel who are at the highest risk of developing pertussis are 
persons who work on pediatric wards and in pediatric centers.
According to ACIP recommendations, it is advisable to promote pertussis vaccinations in 
healthcare personnel and to facilitate access to these vaccinations (e.g. through facilitating 
vaccinations at the place of work, providing free-of-charge vaccines, etc.). Activities aiming at 
performing vaccinations in a vast number of workers should also include educational activi-
ties concerning the illness and its consequences (for the personnel and patients), and informa-
tive activities regarding the vaccines, their safety and effectiveness. It is not recommended to 
do serological tests for pertussis before the vaccination and after it. Recovering from pertussis 
is no contraindication for the vaccination [52].
It was estimated that the costs of including healthcare personnel, who have a direct and close 
contact with patients, in a pertussis vaccination program in the USA could be two times lower 
in a 10-year perspective than controlling pertussis epidemics in healthcare facilities [52].
On the basis of serological tests, it can be estimated that even 25% of healthcare professionals 
have contact with influenza viruses on an annual basis [53]. Interestingly, 25% of persons who 
had direct contact with patients whose serological tests proved past influenza infections did 
not provide disease symptoms in the interview [54]. This might indicate a possible mild course 
of the infection or an infection accompanied with very few symptoms. Nonetheless, these 
persons can still be a source of infection both for patients and for other members of health-
care personnel [54]. Infectious disease epidemics, including influenza outbreaks, in healthcare 
facilities might bring measurable and significant consequences for the finance, for example 
costs of controlling and epidemic outbreaks (patient isolation, implementation of antivirus 
treatment), costs of temporary termination of medical services due to cancellation of admis-
sions, costs of employing special personnel to care about particular patients suffering from 
influenza, consequences for the hospital image—loss of trust among patients, impediments in 
patient visits and legal consequences—and compensation claims [48]. Healthcare profession-
als are exposed to infections through droplets or contact with influenza viruses at the place 
of work and they might become the source of infection for patients. Most of them belong to a 
group which is at a high risk of the severe course of disease and influenza complications due 
to their age and chronic illnesses, for example, respiratory system diseases (bronchial asthma, 
chronic obstructive pulmonary disease), cardiovascular diseases or metabolic diseases (e.g. 
diabetes). According to the studies, 75% of doctors admit that they perform their professional 
duties despite having disease symptoms, which indicate a current respiratory system infec-
tion [52, 53]. Influenza complications, hospitalizations and deaths related to influenza or its 
consequences occur mostly in chronic patients, infants and young children (aged 2–5 years), 
senior citizens and pregnant women [54]. Vaccinations in healthcare personnel are particularly 
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beneficial for those patients who cannot be given a vaccination, for example patients who are 
too young (infants at the age 6 months for whom there are no registered vaccines—it needs 
to be stressed that influenza infections have been observed even in newborns), patients with 
medical contraindications to vaccinations (e.g. occurrence of a strong anaphylactic reaction 
after influenza vaccination confirmed allergy to any component of the vaccine), patients who 
do not respond to vaccination appropriately (e.g. persons aged 85 and more, patients in immu-
nosuppression) and persons who cannot be treated with antiviral medications due to medical 
contraindications (mostly neuraminidase inhibitors). Thus, influenza vaccinations in health-
care personnel constitute an element of cocoon strategy for protective vaccinations [55]. The 
results of published studies indicate that influenza vaccinations in healthcare professionals in 
medical facilities ensure a significant decrease in general mortality and flu-like disease morbid-
ity in patients requiring long-term care [56–58]. Carman et al. [56] showed that achieving 50% 
level of vaccinations in the personnel of a nursing home for the elderly results in the reduction 
of mortality among the elderly residents by 40%. Individual benefits for the personnel arising 
from influenza vaccinations are less documented [56–58]; however, it was observed, for exam-
ple that the number of days absent from work due to respiratory system infections decreased 
and so did the risk of influenza virus infections (88–89% on average) [59, 60]. A slight decrease 
in the number of days absent from work (by approx. 0.5 days) was also obtained in the popu-
lation of vaccinated healthy persons of working age [59, 60]. Salgado et al. [61] showed that 
the number of laboratory-confirmed influenza cases and the percentage of hospital respira-
tory system infections diminished from 42 to 9 and from 32 to 3%, respectively, in a group of 
influenza-vaccinated medical professionals.
Scientific literature gives examples of influenza epidemics in hospital wards which spread 
in patients requiring special care. In 1998, an epidemic broke out in a neonatal intensive care 
unit which resulted in disease cases in 19 out of 54 patients and a death of 1 child. Only 15% 
of the personnel had been vaccinated and 29 persons admitted to taking care of patients while 
having symptoms of a respiratory system infection [62]. In the same year, 10 patients devel-
oped influenza in a bone marrow unit and 1 person died. In this case, 12% of the personnel 
had been vaccinated and five personnel members were at work with disease symptoms [63]. 
Influenza virus outbreaks were also observed in liver transplantation, hematological, neona-
tal and pediatric units (in the last two units, additional risk factors for influenza virus infec-
tions were identified: artificial ventilation system and multiple pregnancy) [64–67]. A group 
of patients who are particularly at risk of hospital epidemics are residents of facilities, which 
render care and treatment services for patients with chronic illnesses. During the occurrence 
of an influenza outbreak in a facility whose residents were at the age of above 65 years, the 
percentage of infected patients in an epidemic season was very high and it could reach even 
60% [68]. The facts that influenza vaccinations in the elderly are not as effective as vaccina-
tions in a younger population (30–40% vs 70–90%), and that influenza epidemics occurred in 
the populations of the residents of nursing homes, where influenza immunization was very 
high and reached even 90%, prove that it is necessary to perform vaccinations in healthcare 
professionals in order to protect the patients [69, 70].
Unfortunately, percentage of medical professionals who are vaccinated against pertussis in 
developed countries is relatively low. According to the studies, although educational activities 
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result in the increased interest in the vaccinations, only a small group of healthcare  personnel 
are vaccinated despite their initial intentions of undergoing a vaccination. Pertussis educa-
tion for medical professionals could solve this problem. Tdpa vaccine is safe and effective. 
Pertussis booster vaccinations for healthcare personnel might be the most effective to dimin-
ish the risk of pertussis cases and the occurrence of hospital infections in healthcare facilities.
7. Benefits and drawbacks of the cocoon strategy for protective 
vaccinations
The main benefit of cocoon strategy is that it decreases the risk of the transmission of an 
infectious disease in the environment of a patient who might become infected but cannot be 
vaccinated. A universal adult pertussis program does not only serve to decrease the disease in 
the overall risk of disease among infants (beyond that which might be achieved with a more 
focused cocoon strategy) but it also protects adults against the disease.
The main drawback of a cocoon strategy is that it is characterized by a low level of recom-
mendation implementations and a small percentage of vaccinated persons, which impairs 
the performance of this strategy. It is critical to the success of a universal program to ensure 
that adequate vaccine coverage is achieved. A comparison of various immunization strate-
gies suggests that the coverage of at least 40% within the adult population is required to 
achieve herd immunity [2]. In practice, achievement of such high indicators is impossible.
Barriers to receiving vaccines by close contacts include lack of knowledge about the disease 
and the benefits of vaccination, time and monetary constraints, forgetting about vaccine rec-
ommendations if previously received.
Although it is recommended to vaccinate all close contacts under a cocoon strategy, vaccina-
tions are frequently limited to mothers, which also influence negatively the effectiveness of 
the strategy. Vaccinations should be universal and cover caregivers of all infants instead of 
being addressed solely to the families of children from risk groups.
To conclude, cocoon strategy for protective vaccinations constitutes a valuable complement to 
universal vaccination programs. Nonetheless, it should not be the only recommended strategy 
but it should be an element of a comprehensive strategy for preventing infectious diseases.
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